Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Nivolumab +/- Ipilimumab in HNSCC After Salvage Surgery
NCT03406247Phase 2Recruiting
- Sponsor
- Gustave Roussy
- Start
- Feb 2018
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in head and neck squamous cell carcinoma (HNSCC), sponsored by Gustave Roussy. Started Feb 2018; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03406247.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03406247.